Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't respond to this immunotherapy for reasons not yet fully understood.
T cells (red) attack cancer cell (white) / Rita Elena Serda, Duncan Comprehensive Cancer Center at Baylor College of Medicine, National Cancer Institute, NIH Share Lights, vitamin, action. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results